Bandingkan Harga & Kinerja Wahana Inti Makmur Tbk. (NASI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Wahana Inti Makmur Tbk. dan Organon Pharma Indonesia Tbk.: Wahana Inti Makmur Tbk. diperdagangkan di Rp165 (kapitalisasi pasar 131,61 M, volume 24 jam 4,22 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Wahana Inti Makmur Tbk. lebih besar dari sisi kapitalisasi pasar. Mana yang lebih baik tergantung tujuan investasimu.
| NASI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 131,61 M | 104,4 M |
Volume | 4,22 jt | — |
Lot | 42,25 rb | — |
Perputaran | 683,98 jt | — |
Harga Rata-rata | 161,9 | — |
Nilai Transaksi | 683,98 jt | — |
Harga Ekuilibrium Indikatif | 165 | — |
Volume Ekuilibrium Indikatif | 1,61 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Wahana Inti Makmur Tbk.
PT Wahana Inti Makmur Tbk (the Company) is established based on Deed of Establishment No. 02 dated February 14, 2015 made by Dr. Tio Jeffrens Maranella, S.H., Notary in Jakarta. The Company started its commercial operations in February 2015.
Selengkapnya di halaman NASI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
